Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Status:
Completed
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
This is a feasibility trial of anti-PDL1/PD1 (pembrolizumab) and stereotactic body radiation
therapy (SBRT) in patients with advanced, platinum-refractory urothelial carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center